{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:01:15Z","timestamp":1774522875535,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinbiochem.2019.10.010","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T01:38:57Z","timestamp":1572053937000},"page":"73-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Comparison of the Quantum Blue\u00ae reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels"],"prefix":"10.1016","volume":"74","author":[{"given":"Vasilije","family":"Novakovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samire","family":"Abdija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia B\u00fckmann","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mogens","family":"Fenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Gredal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja Kemp","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl.1","key":"10.1016\/j.clinbiochem.2019.10.010_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejphar.2009.10.023","article-title":"Ten years of infliximab (Remicade\u00ae) in clinical practice: The story from bench to bedside","volume":"623","author":"Cornillie","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2019.10.010_b0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","article-title":"Targeting TNF-\u03b1 for the treatment of inflammatory bowel disease","volume":"14","author":"Billiet","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0015","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-Alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/MIB.0000000000000003","article-title":"A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease","volume":"20","author":"Vahabnezhad","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0025","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0030","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MPG.0000000000001258","article-title":"Clinical use of infliximab trough levels and antibodies to infliximab in pediatric patients with inflammatory bowel disease","volume":"64","author":"Merras-Salmio","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MPG.0000000000002112","article-title":"Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study","volume":"68","author":"Naviglio","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0040","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3109\/00365521.2015.1027264","article-title":"The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease","volume":"50","author":"Hoekman","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2019.10.010_b0045","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/ecco-jcc\/jjw007","article-title":"Systematic review and meta-analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease","volume":"10","author":"Moore","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.10.010_b0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000394","article-title":"Current practice for therapeutic drug monitoring of biopharmaceuticals in inflammatory bowel disease","volume":"39","author":"Detrez","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0055","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818783613","article-title":"Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels","volume":"11","author":"P\u00e9rez","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2019.10.010_b0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/1756283X17722916","article-title":"Clinical performance of an infliximab rapid quantification assay","volume":"10","author":"Magro","year":"2017","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.10.010_b0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/FTD.0000000000000394","article-title":"Current practice for therapeutic drug monitoring of biopharmaceuticals in inflammatory bowel disease","volume":"39","author":"Nasser","year":"2017","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.clinbiochem.2019.10.010_b0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/MPG.0000000000002410","article-title":"Determination of serum infliximab concentration by point-of-care devices in children with inflammatory bowel disease","volume":"69","author":"Curci","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"6","key":"10.1016\/j.clinbiochem.2019.10.010_b0075","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1515\/cclm-2018-0891","volume":"57","author":"Van den Bossche","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"7","key":"10.1016\/j.clinbiochem.2019.10.010_b0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/apt.13757","article-title":"Portuguese IBD Study Group (GEDII). Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays","volume":"44","author":"Afonso","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.clinbiochem.2019.10.010_b0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"12","key":"10.1016\/j.clinbiochem.2019.10.010_b0090","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","article-title":"Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels","volume":"51","author":"Ruiz-Arg\u00fcello","year":"2013","journal-title":"Clin. Chem. Lab Med."},{"issue":"9","key":"10.1016\/j.clinbiochem.2019.10.010_b0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/1756283X17722915","article-title":"Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays","volume":"10","author":"Afonso","year":"2017","journal-title":"Therap. Adv. Gastroenterol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930582X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930582X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:09:55Z","timestamp":1762114195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201930582X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"alternative-id":["S000991201930582X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.10.010","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the Quantum Blue\u00ae reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}